Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Msn Prasad

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Clinical and Diagnostic Research : JCDR|May 18, 2017
Breast Biomarkers-Comparison on Whole Section and Tissue Microarray SectionSneha S Chavan, Savithri Ravindra, Msn Prasad
Journal of Cancer|February 25, 2014
A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative TumorsJyothi S Prabhu, Aruna Korlimarla, Krisha Desai, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 29, 2017
HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cellsKrisha Desai, Radhika Aiyappa, Jyothi S Prabhu, et al.
Translational Oncology|July 14, 2017
Dissecting the Biological Heterogeneity within Hormone Receptor Positive HER2 Negative Breast Cancer by Gene Expression Markers Identifies Indolent Tumors within Late Stage DiseaseJyothi S Prabhu, Aruna Korlimarla, C E Anupama, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Clinical and Diagnostic Research : JCDR|May 18, 2017
Breast Biomarkers-Comparison on Whole Section and Tissue Microarray SectionSneha S Chavan, Savithri Ravindra, Msn Prasad
Journal of Cancer|February 25, 2014
A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative TumorsJyothi S Prabhu, Aruna Korlimarla, Krisha Desai, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 29, 2017
HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cellsKrisha Desai, Radhika Aiyappa, Jyothi S Prabhu, et al.
Translational Oncology|July 14, 2017
Dissecting the Biological Heterogeneity within Hormone Receptor Positive HER2 Negative Breast Cancer by Gene Expression Markers Identifies Indolent Tumors within Late Stage DiseaseJyothi S Prabhu, Aruna Korlimarla, C E Anupama, et al.
Pageof 1